Endothelial microparticles as markers of endothelial dysfunction

被引:258
作者
Horstman, LL [1 ]
Jy, W [1 ]
Jimenez, JJ [1 ]
Ahn, YS [1 ]
机构
[1] Univ Miami, Sch Med, Dept Med,Div Hematol Oncol, Wallace H Coulter Platelet Lab, Miami, FL 33136 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2004年 / 9卷
关键词
endothelium; endothelial microparticles; leukocyte; coagulation; thrombosis; preeclampsia; eclampsia; purpura; multiple sclerosis; hypertension; review;
D O I
10.2741/1270
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Endothelial microparticles (EMP) are small vesicles released from disturbed endothelial cells (EC). Owing to the central importance of EC injury in thrombotic and inflammatory conditions, assay of EMP as a marker of EC disturbance has come under intensive development by several laboratories. The review begins with established markers of EC injury, commonly soluble markers such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, von Willebrand factor (vWF), etc., pointing out that many of these are in fact mixtures of true soluble molecules with membrane-bound forms, i.e., EMP. Assays of EMP from different labs are reviewed and standardization of assay is recommended. EMP are heterogeneous: those released in activation vs. apoptosis are distinctive in phenotypic markers and procoagulant properties. Application of EMP phenotype analysis can distinguish EC state of activation from apoptosis. Some EMP carry functional vWF with properties different from soluble vWF. Certain EMP bind to and activate monocytes; EMP-monocyte conjugates were found to be a marker of inflammatory disease such as multiple sclerosis (MS), and to enhance transendothelial migration of leukocytes in vitro. Clinical studies have revealed elevated plasma levels of EMP in lupus anticoagulant ( LA), multiple sclerosis ( MS), thrombotic thrombocytopenic purpura (TTP), coronary artery disease (CAD), hypertension, preeclampsia, and diabetes. Further refinement of EMP assay could open new windows for evaluating and monitoring endothelial injury in thrombotic and inflammatory disorders.
引用
收藏
页码:1118 / 1135
页数:18
相关论文
共 142 条
  • [1] Vascular dementia in patients with immune thrombocytopenic purpura
    Ahn, YS
    Horstman, LL
    Jy, W
    Jimenez, JJ
    Bowen, B
    [J]. THROMBOSIS RESEARCH, 2002, 107 (06) : 337 - 344
  • [2] Idiopathic thrombocytopenic purpura: Pathophysiology and management
    Ahn, YS
    Horstman, LL
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (Suppl 2) : 123 - 131
  • [3] Activated platelet aggregates in thrombotic thrombocytopenic purpura: Decrease with plasma infusions and normalization in remission
    Ahn, YS
    Jy, W
    Kolodny, L
    Horstman, LL
    Mao, WW
    Valant, PA
    Duncan, RC
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (02) : 408 - 415
  • [4] ANDREW JH, 1993, IMMUNOL TODAY, V14, P506
  • [5] Anker P, 2002, CLIN CHEM, V48, P1210
  • [6] Arnout J, 1996, THROMB HAEMOSTASIS, V75, P536
  • [7] ARTEAGA RB, 2003, BLOOD
  • [8] Atsumi T, 1997, THROMB HAEMOSTASIS, V77, P222
  • [9] The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection
    Aupeix, K
    Hugel, B
    Martin, T
    Bischoff, P
    Lill, H
    Pasquali, JL
    Freyssinet, JM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) : 1546 - 1554
  • [10] Bajaj MS, 2001, THROMB HAEMOSTASIS, V86, P959